Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Stellar Biotechnologies Provides Quarterly Update/Outlook and Comments on CBS News Cancer Vaccine Story

Abstract:
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (PINKSHEETS: SBOTF) has been advancing on several fronts over their first quarter as a public company, and expects to achieve new milestones before year end.

Stellar Biotechnologies Provides Quarterly Update/Outlook and Comments on CBS News Cancer Vaccine Story

Port Hueneme, CA | Posted on October 13th, 2010

The Company would like to comment on the recent, featured CBS Evening News report (see video link below) by Dr. Sanjay Gupta on a KLH-based glioblastoma vaccine in development by Celldex Therapeutics about which it has received enquiries.

On October 4th CBS Evening News with Katie Couric featured Dr. Sanjay Gupta in a story about a KLH-based brain cancer vaccine being tested in patients at Duke University for Celldex Therapeutics (*).

John S. Sundsmo, Ph.D., Stellar's VP of Research & Intellectual Property Management, said "Molecular biology is identifying genetic modifications in certain cancer cells that constitute targets for cancer vaccines. Dr. Sanjay Gupta discusses the initial successes observed with glioblastoma multiforme (GBM), normally a rapidly progressing form of brain cancer. The cancer vaccine in the report was produced by Celldex Therapeutics by coupling a cancer-specific protein onto the immune carrier protein KLH. The very early stage results for some patients show signs in MRIs that their tumors may have decreased. While the immune system is highly effective in protecting us against bacteria, cancer cells are extremely difficult to kill and effective killing is mediated by a specialized class of killer T-cells. In this respect, KLH, the hemocyanin protein from the giant keyhole limpet, can be seen as rather unique. KLH stimulates highly effective cell-mediated immunity that results in the production of cancer-killing T-cells. This is offering new hope for patients with previously incurable cancers." Discussions between Celldex and Stellar have been underway.

Quarterly Update/Outlook

Achievements

On September 9th Stellar announced that it had filed for patent protection of inventions related to its Immunogenic (IMG) KLH technology platforms (1)
On September 13th the Company announced a milestone payment from Bayer Innovation (a wholly owned subsidiary of international pharmaceutical company, Bayer AG: (PINKSHEETS: BAYRY) and the achievement of a critical milestone in our Joint Development Agreement (2)
On September 29th Stellar disclosed a CDN $1.05M private placement with a strategic investor and the retirement of 1.66 million shares to the treasury (3)
On September 30th the Company announced receipt of $288,000 from a single biotechnology and immunotherapy products company developing KLH-based therapeutic vaccines for Rheumatoid Arthritis and Lupus for fiscal year ending August 30, 2010 (4)

2010 Outlook

first Annual General Meeting since public
status of grants that have been applied for by Stellar's California subsidiary
launch date for sales of immunotox products aimed at the pre-clinical market, related to our ongoing research designed to advance Stellar's immune response diagnostic platform
research and regulatory developments related to our new IMG KLH product platform
advancements related to our relationships with Bayer Innovation and several new customers
in and out-licensing and long-term supply agreements, as well as new KLH orders.

(*) (3 minute video: www.cbsnews.com/video/watch/?id=6927121n&tag=related;photovideo
a short article here: www.acsh.org/factsfears/newsID.1920/news_detail.asp)

(1) www.stellarbiotechnologies.com/investors/news_releases/index.php?&content_id=43
(2) www.stellarbiotechnologies.com/investors/news_releases/index.php?&content_id=44
(3) www.stellarbiotechnologies.com/investors/news_releases/index.php?&content_id=45
(4) www.stellarbiotechnologies.com/investors/news_releases/index.php?&content_id=46


Statements in these press releases other than purely historical factual information, including statements relating to revenues or profits, or the Company's future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. These news releases do not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.

####

About Stellar Biotechnologies
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

For more information, please click here

Contacts:
Darrell Brookstein, Executive VP, Business Development & Finance

Copyright © Stellar Biotechnologies

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

'Lasers rewired': Scientists find a new way to make nanowire lasers: Berkeley Lab, UC Berkeley scientists adapt next-gen solar cell materials for a different purpose February 12th, 2016

Breaking cell barriers with retractable protein nanoneedles: Adapting a bacterial structure, Wyss Institute researchers develop protein actuators that can mechanically puncture cells February 12th, 2016

Replacement of Toxic Antibacterial Agents Possible by Biocompatible Polymeric Nanocomposites February 12th, 2016

Properties of Polymeric Nanofibers Optimized to Treat Damaged Body Tissues February 12th, 2016

Nanomedicine

Breaking cell barriers with retractable protein nanoneedles: Adapting a bacterial structure, Wyss Institute researchers develop protein actuators that can mechanically puncture cells February 12th, 2016

Replacement of Toxic Antibacterial Agents Possible by Biocompatible Polymeric Nanocomposites February 12th, 2016

Properties of Polymeric Nanofibers Optimized to Treat Damaged Body Tissues February 12th, 2016

SLAC X-ray laser turns crystal imperfections into better images of important biomolecules: New method could remove major obstacles to studying structures of complex biological machines February 11th, 2016

Announcements

Graphene leans on glass to advance electronics: Scientists' use of common glass to optimize graphene's electronic properties could improve technologies from flat screens to solar cells February 12th, 2016

Breaking cell barriers with retractable protein nanoneedles: Adapting a bacterial structure, Wyss Institute researchers develop protein actuators that can mechanically puncture cells February 12th, 2016

Replacement of Toxic Antibacterial Agents Possible by Biocompatible Polymeric Nanocomposites February 12th, 2016

Properties of Polymeric Nanofibers Optimized to Treat Damaged Body Tissues February 12th, 2016

Patents/IP/Tech Transfer/Licensing

New thin film transistor may lead to flexible devices: Researchers engineer an electronics first, opening door to flexible electronics February 10th, 2016

Joint Efforts by Iranian, Malaysian Scientists Produce Antibacterial Coatings for Isolated Areas February 4th, 2016

Silicon-based metamaterials could bring photonic circuits February 1st, 2016

Therapeutic Solutions International Licenses Dexosome Clinical Stage Cancer Immunotherapy Product From Gustave Roussy European Cancer Centre: FDA Cleared Immuno-Oncology Technology to Resume Clinical Development for Solid Tumor Patients January 27th, 2016

Financial Reports

Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015

Haydale Announce Year End Results November 3rd, 2015

Harris & Harris Group to Host Conference Call on Third-Quarter 2015 Financial Results on November 12, 2015 October 23rd, 2015

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

Nanobiotechnology

Breaking cell barriers with retractable protein nanoneedles: Adapting a bacterial structure, Wyss Institute researchers develop protein actuators that can mechanically puncture cells February 12th, 2016

Replacement of Toxic Antibacterial Agents Possible by Biocompatible Polymeric Nanocomposites February 12th, 2016

Properties of Polymeric Nanofibers Optimized to Treat Damaged Body Tissues February 12th, 2016

SLAC X-ray laser turns crystal imperfections into better images of important biomolecules: New method could remove major obstacles to studying structures of complex biological machines February 11th, 2016

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic